CS151187A2 - Method of carbacycline derivatives' cyclodextrin's clathrates production - Google Patents

Method of carbacycline derivatives' cyclodextrin's clathrates production

Info

Publication number
CS151187A2
CS151187A2 CS871511A CS151187A CS151187A2 CS 151187 A2 CS151187 A2 CS 151187A2 CS 871511 A CS871511 A CS 871511A CS 151187 A CS151187 A CS 151187A CS 151187 A2 CS151187 A2 CS 151187A2
Authority
CS
Czechoslovakia
Prior art keywords
clathrates
cyclodextrin
production
carbacycline derivatives
carbacycline
Prior art date
Application number
CS871511A
Other languages
English (en)
Other versions
CS270558B2 (en
Inventor
Werner Dr Skuballa
Helmut Prof Vorbruggen
Helmut Dr Dahl
Claus-Steffen Dr Sturzebecher
Karl-Heinz Dr Thierauch
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of CS151187A2 publication Critical patent/CS151187A2/cs
Publication of CS270558B2 publication Critical patent/CS270558B2/cs

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
    • C07C405/0075—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system
    • C07C405/0083—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system which is only ortho or peri condensed, e.g. carbacyclins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CS871511A 1986-03-07 1987-03-06 Method of carbacycline derivatives' cyclodextrin's clathrates production CS270558B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3608088A DE3608088C2 (de) 1986-03-07 1986-03-07 Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten

Publications (2)

Publication Number Publication Date
CS151187A2 true CS151187A2 (en) 1989-11-14
CS270558B2 CS270558B2 (en) 1990-07-12

Family

ID=6296073

Family Applications (1)

Application Number Title Priority Date Filing Date
CS871511A CS270558B2 (en) 1986-03-07 1987-03-06 Method of carbacycline derivatives' cyclodextrin's clathrates production

Country Status (22)

Country Link
US (1) US4886788A (cs)
EP (1) EP0259468B1 (cs)
JP (2) JPH07107020B2 (cs)
AT (1) AT397084B (cs)
AU (2) AU609390B2 (cs)
CA (1) CA1309087C (cs)
CH (1) CH672313A5 (cs)
CS (1) CS270558B2 (cs)
DD (1) DD258942A5 (cs)
DE (3) DE3608088C2 (cs)
ES (1) ES2004543A6 (cs)
FI (1) FI92388C (cs)
GB (2) GB2189783A (cs)
GR (1) GR870363B (cs)
HU (1) HU198906B (cs)
IE (1) IE59760B1 (cs)
IL (1) IL81802A (cs)
NO (1) NO173440C (cs)
NZ (1) NZ219508A (cs)
SU (1) SU1632371A3 (cs)
WO (1) WO1987005294A1 (cs)
ZA (1) ZA871663B (cs)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663316A (en) * 1985-06-28 1987-05-05 Warner-Lambert Company Antibiotic clathrates and pharmaceutical compositions thereof
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
ATE122563T1 (de) * 1989-07-27 1995-06-15 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von 15-keto-prostansäure-derivaten zur herstellung eines medikaments für die verbesserung der ausscheidung des kaliumions.
DE3933523A1 (de) * 1989-10-05 1991-04-11 Schering Ag Antimetastatisch wirkende mittel
DE4010355A1 (de) * 1990-03-28 1991-10-02 Schering Ag Bicyclo(3.3.0)octan-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE4104606C1 (cs) * 1991-02-12 1992-10-15 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US5221735A (en) * 1991-02-25 1993-06-22 Hoffmann-La Roche Inc. Cyclodextrin-polyene inclusion complexes
DE4135193C1 (cs) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US6103403A (en) * 1997-05-15 2000-08-15 University Of Kentucky Research Foundation Intellectual Property Development Clathrate structure for electronic and electro-optic applications
DE19808634A1 (de) * 1998-02-24 1999-08-26 Schering Ag Mantel für eine pharmazeutische Zusammensetzung
DE19828881A1 (de) * 1998-06-22 1999-12-23 Schering Ag Oxidationsinhibitor bei Prostan-Derivaten
DE10225551A1 (de) * 2002-06-06 2003-12-24 Schering Ag Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
EP1976828B1 (en) 2005-12-29 2016-12-21 Celtaxsys, Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
EP2055305A1 (en) * 2006-08-11 2009-05-06 Taisho Pharmaceutical Co. Ltd. External preparation comprising prostaglandin derivative
CA2666143A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
AR063280A1 (es) 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN105218565A (zh) * 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
CN102753556B (zh) 2009-10-14 2015-05-13 泽农医药公司 螺-羟吲哚化合物的合成方法
NZ601667A (en) 2010-02-26 2014-10-31 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
HK1205114A1 (en) 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
EP3551611A1 (en) 2016-12-09 2019-10-16 Celtaxsys Inc. Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase
EP3551608A1 (en) 2016-12-09 2019-10-16 Celtaxsys Inc. Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
JP7145154B2 (ja) 2016-12-09 2022-09-30 セルタクシー、エルエルシー ロイコトリエンa4ヒドロラーゼの阻害剤
HU231212B1 (hu) * 2018-04-16 2021-11-29 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Eljárás iloprost előállítására
RU2741848C1 (ru) * 2019-03-16 2021-01-29 Иванова Мария Ивановна Способ получения клатратных комплексов летучих веществ
WO2023037934A1 (ja) * 2021-09-13 2023-03-16 富士フイルム株式会社 ビシクロアルカン化合物の包摂体の製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (cs) * 1970-06-10 1975-02-04
AU476695B2 (en) * 1974-01-15 1975-07-17 Ono Pharmaceutical Co. Ltd Clathrate prostaglandins and compositions containing same
HU179141B (cs) * 1977-09-23 1982-08-28
GB2017699B (en) * 1978-03-31 1983-01-12 Ono Pharmaceutical Co 6,9-methano-pgi2 analogues
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE2950027A1 (de) * 1979-12-10 1981-06-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin 9-chlor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel
JPS56150039A (en) * 1980-04-22 1981-11-20 Sankyo Co Ltd Clathrate compound of prostacycline derivative
DE3126924A1 (de) * 1981-07-03 1983-01-20 Schering Ag, 1000 Berlin Und 4619 Bergkamen 9-fluor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel
JPS5818357A (ja) * 1981-07-28 1983-02-02 Ono Pharmaceut Co Ltd 6,9−メタノ−pgi↓2及び6,9−メタノ−pgi↓2類似化合物の安定化組成物及びその製造方法
JPS58116423A (ja) * 1981-12-28 1983-07-11 Sumitomo Chem Co Ltd メタノプロスタサイクリン製剤組成物
JPS58192821A (ja) * 1982-04-30 1983-11-10 Dainippon Pharmaceut Co Ltd 脳神経細胞の酸素欠乏性疾患の治療剤
US4517202A (en) * 1982-05-28 1985-05-14 May & Baker Limited Prostaglandin analogues
JPS59141536A (ja) * 1983-02-01 1984-08-14 Sumitomo Chem Co Ltd 新規ビシクロオクタン誘導体
DE3306123A1 (de) * 1983-02-18 1984-09-06 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2547818B1 (fr) * 1983-05-24 1986-09-05 May & Baker Ltd Nouveaux analogues de prostaglandines, leur preparation, les compositions pharmaceutiques qui les contiennent et les intermediaires-cles pour les preparer
DE3405181A1 (de) * 1984-02-10 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS6144819A (ja) * 1984-08-09 1986-03-04 Sagami Chem Res Center プロスタグランジンi2類縁化合物を含有する循環改善作用を有する薬剤
EP0171992B1 (en) * 1984-08-09 1990-06-06 Mitsubishi Kasei Corporation Pharmaceuticals containing prostaglandin i2
US4757087A (en) * 1985-03-19 1988-07-12 Sankyo Company Limited Carbacyclin derivatives
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten

Also Published As

Publication number Publication date
IE59760B1 (en) 1994-03-23
ATA900787A (de) 1993-06-15
CA1309087C (en) 1992-10-20
NZ219508A (en) 1990-08-28
NO173440B (no) 1993-09-06
JPH07107020B2 (ja) 1995-11-15
AT397084B (de) 1994-01-25
WO1987005294A1 (fr) 1987-09-11
SU1632371A3 (ru) 1991-02-28
DE3790121D2 (en) 1988-03-10
FI874406A7 (fi) 1987-10-07
ZA871663B (en) 1987-08-28
GR870363B (en) 1987-06-30
GB2199031B (en) 1990-01-10
AU6988687A (en) 1987-09-10
AU609390B2 (en) 1991-05-02
GB8704982D0 (en) 1987-04-08
EP0259468B1 (de) 1991-05-15
GB2189783A (en) 1987-11-04
CS270558B2 (en) 1990-07-12
GB8725695D0 (en) 1987-12-09
AU7160987A (en) 1987-09-28
HU198906B (en) 1989-12-28
JPS63502665A (ja) 1988-10-06
NO874632D0 (no) 1987-11-06
HUT45484A (en) 1988-07-28
JPH08193046A (ja) 1996-07-30
DE3608088C2 (de) 1995-11-16
NO173440C (no) 1993-12-15
IL81802A (en) 1991-07-18
JP2634787B2 (ja) 1997-07-30
FI92388C (fi) 1994-11-10
DE3608088A1 (de) 1987-09-10
DD258942A5 (de) 1988-08-10
CH672313A5 (cs) 1989-11-15
EP0259468A1 (de) 1988-03-16
GB2199031A (en) 1988-06-29
IE870586L (en) 1987-09-07
DE3770085D1 (de) 1991-06-20
IL81802A0 (en) 1987-10-20
ES2004543A6 (es) 1989-01-16
FI92388B (fi) 1994-07-29
US4886788A (en) 1989-12-12
FI874406A0 (fi) 1987-10-07
NO874632L (no) 1987-11-06

Similar Documents

Publication Publication Date Title
CS747588A2 (en) Method of 5-deoxy-5-fluorcytidine's new derivatives production
HU912420D0 (en) Process for producing 9(11)-dehydro-steroid derivatives
HUT45484A (en) Process for producing cyclodextrin inclusion compounds of carbacycline derivatives and pharmaceutics comprising the same
GB2189245B (en) Process for producing modified cyclodextrins
HU906465D0 (en) Process for producing 3 beta-/4(s)-aryl-oxazolidine-2-one-3-il/-azetidine-2-one derivatives
HUT45241A (en) Process for producing naphthothiazepinone derivatives
HUT46029A (en) Process for producing inosose derivatives
HUT47074A (en) Improved process for producing 1-amino-indane derivatives
CS189389A2 (en) Method of cephalosporin's new derivatives production
CS705788A2 (en) Method of purine's new derivatives production
CS567989A2 (en) Method of substituted 1,3,5-triazintriones production
CS412388A2 (en) Method of 7-piperazino-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxyl acid's derivatives production
EP0268820A3 (en) Process for producing 2-acylfuran derivatives
CS872287A2 (en) Method of new triazine's derivatives production
CS837885A2 (en) Method of silibinene's new derivatives production
HU913584D0 (en) Process for the production of imidazolyl-carbonyl-oxy-labdane derivatives
HUT48571A (en) Process for production of substituated 3,5-dichlor-2,4-difluor-benzol
PL267418A1 (en) Method of obtaining derivatives of 2,3-dihydrofurene
CS960486A2 (en) Method of pregnale-21-acid's 16,17-acetal-substituted derivatives production
CS520584A2 (en) Method of 1-sulpho-2-azetidinone's derivatives production
CS910288A2 (en) Method of dioxazocine's derivatives production
PT85392A (en) Process for the preparation of 2,4-diamino-3-oxy-6-piperidylpurimidine
HUT46035A (en) Process for producing 16-dehydro-20-oxopregnane derivatives
CS292087A2 (en) Method of ergolen derivatives production
PL266240A1 (en) Method of obtaining derivatives of 1,3,2-oxazaphosphorinate

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MK4A Patent expired

Effective date: 20020306